Biomarker detects graft-versus-host-disease in cancer patients after bone marrow transplant

Test may help rapid identification of severe graft-versus-host disease of the intestine in hematopoietic cell transplant patients with leukemia, lymphoma or other blood disorders

This article is part of the Cancer Center's News Archive, and is listed here for historical purposes. The information and links may no longer be up-to-date.

-added 10/21/2011

Ann Arbor - A University of Michigan Health System-led team of researchers has found a biomarker they believe can help rapidly identify one of the most serious complications in patients with leukemia, lymphoma and other blood disorders who have received a transplant of new, blood-forming cells.

Biomarker detects graft-versus-host-disease in cancer patients after bone marrow transplant

After a bone marrow transplant, elevated blood levels of REG3-alpha protein, shown here in brown, are an indicator of intestinal graft-versus-host disease, a U-M study found.

Read the abstractgoing to a new website

Known as a hematopoietic stem cell transplant, these patients receive bone marrow or peripheral blood stem cells from a matched donor who is either a family member or an unrelated volunteer.

The most common fatal complication of this type of transplant is graft-versus-host disease (GVHD), where the newly transplanted immune system of the donor attacks the patient's skin and internal organs. Up to 30 percent of recipients develop GVHD in their gastrointestinal tract, which is the organ most resistant to treatment.

Without invasive tests such as biopsies, however, GVHD can be difficult to distinguish from other causes of gastrointestinal distress, such as infection or side effects from medication.

The U-M team tested blood samples from over 1,000 patients who were treated in Ann Arbor, Germany and Japan.

"We believe we've found a reliable biomarker in the patients' blood that is specific to graft-versus-host disease and therefore can help us to rapidly identify patients for whom standard treatment is likely to be insufficient," says James L.M. Ferrara, M.D.going to a new website, co-lead author of the study and director of the U-M Combined Blood and Marrow Transplant Program. "This marker can also tell us whether a patient is likely to respond to therapy and may lead to an entirely new risk assessment for the disease. The findings were recently published online ahead of print publication in the journal Bloodgoing to a new website.

The marker, known as regenerating islet-derived 3-alpha (REG3-alpha), doesn't prevent patients from still needing a biopsy, Ferrara cautions, but taken with other predictive indicators, it could help doctors to ensure patients get the most appropriate treatment as early as possible.

Doctors at U-M hope to start using the test clinically in early 2012.

Funding: The research was supported by grants from the National Institutes of Healthgoing to a new website, Hartwell Foundation and Doris Duke Charitable Foundation.

Disclosure: The authors report no potential conflicts of interest. The University is presently looking for licensing partners to help bring the technology to market.

Additional U-M authors: Andrew C. Harris, M.D.; Joel K. Greenson, M.D.; Thomas M. Braun, Ph.D.; John E. Levine, M.D.; Sung W.J. Choi, M.D.; Mark Vander Lugt, M.D.; Pavan Reddy, M.D.; Sophie Paczesny, M.D.

View the full list of authors and read the abstract of the papergoing to a new website.

Resources

U-M Cancer AnswerLine, 800-865-1125

Clinical trials at U-M, www.UMClinicalStudies.orggoing to a new website.

 

Written by: Ian Demsky. Contact: 734-764-2220.

back to top